{"id":"adalimumab-pfs-and-pen","safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"10%","effect":"Headache"},{"rate":"10%","effect":"Fatigue"},{"rate":"5%","effect":"Nausea"},{"rate":"5%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Adalimumab is a fully human monoclonal antibody that selectively binds to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with cell surface TNF receptors. This action prevents TNF-alpha from inducing inflammation and cell death.","oneSentence":"TNF-alpha inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:15.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid Arthritis"},{"name":"Psoriatic Arthritis"},{"name":"Ankylosing Spondylitis"},{"name":"Crohn's Disease"},{"name":"Ulcerative Colitis"}]},"trialDetails":[{"nctId":"NCT05090124","phase":"NA","title":"Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2022-11-04","conditions":"Rheumatoid Arthritis","enrollment":46},{"nctId":"NCT03983876","phase":"PHASE1","title":"PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-07-01","conditions":"Phase 1","enrollment":207},{"nctId":"NCT02565810","phase":"PHASE2","title":"An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2015-09","conditions":"Rheumatoid Arthritis","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Adalimumab PFS and Pen","genericName":"Adalimumab PFS and Pen","companyName":"Samsung Bioepis Co., Ltd.","companyId":"samsung-bioepis-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TNF-alpha inhibitor Used for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}